Skip to content
Home/Companies/Biotech/ObsEva

ObsEva

Biotech·Switzerland·Exited 2017·Held 2yr
Entry
2015
Hold
2yr
Exit
2017

Who owns ObsEva?

ObsEva is a Swiss Biotech company, formerly owned by Sofinnova Partners, exited in 2017 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VIII · 2015 · Life Sciences VC

Key facts

HQSwitzerland
SectorBiotech
Exit Type
IPO
Exit Year
2017

More from Sofinnova Capital VIII

Other portfolio companies in the same fund.

VectivBio
Exited 2023
BiotechSwitzerland· 2017
to Ironwood Pharmaceuticals
Breath Therapeutics
Exited 2019
BiotechGermany· 2016
to Zambon
Corvidia Therapeutics
Exited 2020
BiotechUS· 2016
to Novo Nordisk
Delinia
Exited 2017
BiotechUK· 2016
to Celgene
ENYO Pharma
ENYO Pharma
Active
BiotechFrance· 2016
ReCor Medical
Exited 2018
MedTechUS· 2016
to Otsuka Holdings

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ObsEva?

ObsEva was formerly owned by Sofinnova Partners, exited in 2017. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue